Does DOSTARLIMAB-GXLY Cause Immune-mediated hepatitis? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Immune-mediated hepatitis have been filed in association with DOSTARLIMAB-GXLY. This represents 1.2% of all adverse event reports for DOSTARLIMAB-GXLY.
6
Reports of Immune-mediated hepatitis with DOSTARLIMAB-GXLY
1.2%
of all DOSTARLIMAB-GXLY reports
0
Deaths
1
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From DOSTARLIMAB-GXLY?
Of the 6 reports, 1 (16.7%) required hospitalization, and 2 (33.3%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DOSTARLIMAB-GXLY. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does DOSTARLIMAB-GXLY Cause?
Off label use (51)
Rash (42)
Death (28)
Malignant neoplasm progression (28)
Fatigue (22)
Neuropathy peripheral (20)
Pyrexia (20)
Product use in unapproved indication (19)
Thrombocytopenia (16)
Hypothyroidism (14)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
PEMBROLIZUMAB (549)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
LENVATINIB (86)
PEMETREXED (86)
Which DOSTARLIMAB-GXLY Alternatives Have Lower Immune-mediated hepatitis Risk?
DOSTARLIMAB-GXLY vs DOTATATE GALLIUM GA-68
DOSTARLIMAB-GXLY vs DOTHIEPIN
DOSTARLIMAB-GXLY vs DOXAZOSIN
DOSTARLIMAB-GXLY vs DOXAZOSIN\DOXAZOSIN
DOSTARLIMAB-GXLY vs DOXEPIN